UpdatesPress Release
SMS Pharma's Q1 revenue rose 6% YoY to ₹207 Cr, with PAT up 8% to ₹20.20 Cr, maintaining 20% EBITDA.
SMS Pharmaceuticals LimitedSMSPHARMA · Filed with the exchange
Growth was driven by high-value APIs.
The ₹280 Cr capex is progressing, alongside a ₹50 Cr investment in peptide R&D for a future product pipeline.
No comments yet. Be the first.